Therefore, we suggest that clinical use of PARP inhibitors should be carefully considered, especially for cancer patients with bone metastasis, elderly patients with a high risk of fractures, and pediatric patients whose level of bone metabolism is being monitored. The gene discussed is PARP1; the disease is cancer.